London South East were delighted to welcome Incanthera to our April Investor Webinar (6.04.2021), where Chairman Tim McCarthy and CEO Dr Simon Ward presented and took questions. Watch the full interview here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East and have access to Premium Chat. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Happy to be able to pick up more shares at the placing price this morning - I actually missed out on the open offer completely due to being taken to hospital that weekend and didn't get out until the Wednesday. Have bought about the same amount in the market now anyway.
If it's good enough for Octopus to stick nearly £2m in it's certainly good enough for me :)
This will fly soon!
Dr Huw Jones, Evgen CEO, commented: "We are pleased to see such progress on a potential vaccine against COVID-19. Recently ARDS has been heavily associated with COVID-19 as it affects the respiratory tract, but it is and will remain a condition in its own right long after we have beaten the pandemic and will continue to be a huge problem for patients. There is a considerable unmet need for effective treatments for ARDS and the outcome of our study will hopefully show how we can use SFX-01 in a serious respiratory condition regardless of the infective agent involved."
The UK must prepare for a "hard winter" because the population immunity to respiratory viruses other than Covid could be lower than usual, one of England's top medics has warned.
Dr Susan Hopkins said the NHS must be "ready" for surges in flu and other similar illnesses.
It comes ahead of England's first step towards easing lockdown, with all pupils returning to school on Monday.
Most pupils have been learning from home since Christmas.
Dr Hopkins, who is in charge of Public Health England's Covid strategy, said the UK needed to be "better prepared" than it was last autumn, when new, faster-spreading variants of the virus emerged.
These drove infection rates up and forced further lockdown measures over the winter.
Dr Hopkins told the BBC's The Andrew Marr Show: "I think we have to prepare for a hard winter, not only with coronavirus, but we've had a year of almost no respiratory viruses of any other type. And that means, potentially the population immunity to that is less.
"So we could see surges in flu. We could see surges in other respiratory viruses and other respiratory pathogens."
Dr Hopkins said her role as a government advisor was to "prepare for worst-case scenarios".
Another 40% plus of shareholding disclosures to come and so every chance of another Major player or two to join the party. DSBM's assessment on the first 60 SFX-01 Covid/Ards patients expected early Q2, ie next month, and so I reckon Huw could have an update or two before that, on the SHP2 cancer target and also the Glioblastoma target and maybe even an update on the breast cancer programme....Exciting times for all invested....there's not many other Bio's around, fully funded with so many shots on multiple targets attracting investment from the leading players in the market....all for 8p a share!!!???? :-)))
We needed a major player as an investor , box ticked
We needed cash, box ticked
Now we need solid results and a good report from the DSMB ...
Waiting to get that box ticked ....
They're not here for a quick buck imho, and given the size of their investment, must be supremely confident in Evgen's prospects and potential going forward....the association with Jim Mellon s highly significant and speaks volumes.....More disclosures this coming week and newws from huw at anytime. Gla holders .....Evgen is all set fro growth and is attracting hgh quality shareholders......the market leader in the case of Octopus....On and UP!!! ;-)
We’re part of Octopus Group
Established in 2000, Octopus is a group of businesses investing in people, ideas and industries that change the world.
We will see over the next few weeks how serious they are. If the share price has a resistance to rise as they are selling shares at a pegged profit margin, 10,20% ect this could have a sub 10p ceiling for a very long time. News will create a rise that they sell into.
The share has now equalled placement price, how long it stays here will be dependant on the acts of large placees and development news.
My buy back in target has been reached. Strategy dependant on monitoring the next resistance.
Yep, a solid substantial long term investment by a market leader, very impressive indeed easyp, and maybe missed by most of the market given the timing of Friday's disclosure.....follow the money.....more disclosures to come this week. Gla ;-)
The 8% impressed me, this is no 2% dabble by an investment manager hedging their bets. A serious punt imo.
Who are the 5 most powerful venture capital funds in Britain?
9 Feb 2021
The 5 most powerful venture capital funds in Britain in terms of assets under management are: Octopus Investments, Balderton Capital, Atomico, BGF and Highland Europe.
A very strong indication on why Jim Mellon and maybe Octopus bought in. Gla :-)
NEWS RELEASE 2-FEB-2021
Aging-US: Sulforaphane promotes C. elegans longevity and healthspan
"The results in this Aging-US research output, indicate that sulforaphane prolongs the lifespan and healthspan of C. elegans through insulin/IGF-1 signaling."
Here, the authors asked whether sulforaphane may influence the lifespan and healthspan of C. elegans.
They found that sulforaphane significantly extends the lifespan of C. elegans and delays age-related phenotype changes.
The analysis of wild-type C. elegans and 9 mutant strains revealed that sulforaphane inhibited DAF-2 insulin/insulin receptor signaling and thereby increased DAF-16 nuclear translocation, resulting in the expression of the sod-3, mtl-1 and gst-4 target genes, which are known mediators of longevity in C. elegans.
The Herr Research Team concluded in their Aging-US Research Paper, "we are the first to report that sulforaphane prolongs the lifespan and increases the healthspan of C. elegans through the inhibition of DAF- 2/insulin/IGF-1 signaling and the activation of DAF- 16/FOXO nuclear transcription in C. elegans. Our study provides a promising hint regarding the suitability of sulforaphane as a new anti-aging drug. However, additional studies in invertebrates and mammalian model organisms are necessary to expand our findings."
Boom time - Jim Mellon
Longevity science will, I think, lead to the biggest stock market boom ever. It will make the recent medical cannabis boom look like nothing. For the first time in the history of mankind, the elixir of youth, the promise of living a longer life, will actually come true.
There is no one pill that you can take, but a combination of several pharmaceuticals, gene therapies, gene-related technology and treatments could extend your lifespan to 120.
I’m confident in predicting that the science of longevity will represent the biggest industry on the planet within 20 years, and that it will be affordable for everyone after about ten years of commercial exploitation.
Wear and tear
It is important to note that we’re not predestined to die. But as time goes on, the healing process of our body gets overwhelmed – wear and tear overwhelms repair.
We gradually go into a process called ‘loss of homeostasis’, which signals that our inner chemical balance is beginning to get upset, which eventually results in death.
There are some creatures out there, such as the C. elegans worm, which Google’s ageing company Calico is studying, that are made up of atoms and molecules just like us but don’t die naturally. Science has shown that the lifespan of a worm can be increased by up to 20 times using genetic manipulation.
Similar principles can apply to humans. There is a huge amount of bioscience activity in the UK, which is not widely known. There have been negative developments in the form of Neil Woodford’s investments and the government’s lack of funding in this area.
But now people like Sir John Bell are spearheading major efforts to build a home-grown industry. Increasingly, the nexus between VC universities and scientist-entrepreneurs that’s made the US so successful in this field is developing in the UK.
More Juvenescence employees are based here than anywhere else, so we’re very much British. It’s very important to us that the UK retains its status as the second major centre for life sciences in the world.
For any newbies looking in for the first time, Jim Mellon is the Chairman of Juvensescene who signed a licensing agreement with Evgen 15/9/20, and so maybe one of the many possible reasons why Octopus have bought 21.8m shares representing 7.96%......Exciting times....Gla ;-)
Details of the Agreement
The license is for exclusive rights to exploit certain patents and know-how for all non-pharmaceutical applications in the United States, with options for the other major markets namely, Europe, Asia and the Rest of the World. Evgen will receive upfront and milestone payments of up to $10.5m, and in addition, royalties on sales. Evgen received an initial payment of $250k on signing of the Agreement.
Barry Clare, Executive Chairman of Evgen, said: "This deal is a strong demonstration of the broad potential for our sulforaphane platform and achieves monetisation in an area which is outside our focus of therapeutic development in the Nrf2 and STAT3 pathways. Juvenescence has a science-driven approach to nutritional health products and brings in-depth experience in this sector. We are delighted to have them as a partner. "
Colin Watts, Chief Executive Officer of JuvLife Division, said : "We are pleased to reach an agreement with Evgen to leverage their scientific technology and expertise to create a differentiated and innovative new product for the global consumer nutritional health market. Juvenescence has built a reputation as a broad-based healthcare company in the Longevity space through strong partnerships with scientific leaders in their specific areas and we are delighted to have such a partner in Evgen."
As far as her views on Longevity as a sector goes, Choudry has spent time with Juvenescence’s Jim Mellon and the people who manage his investment funds.
“There were interesting views on lifespan versus health span, and we asked ourselves whether Longevity is a space we should be looking at?” she says. “We think it is because the areas that we want to look at are those where we think there is a large opportunity or big global challenges that we could be solving. Longevity certainly ticks that box, the aging population is something that is at the front of our mind. Probably more so around health span rather than lifespan – how are these people able to keep good health into their later years. Those are some of the areas that we are looking at within our future of health team.”
0 0 0
Octopus Investments Octopus Venutures, all part of the Octopus Group, who now hold 8% of Evgen...I wonder if Jim Mellon has bought in??? Gla ;-)
Biohacking and the future of health and Longevity
February 14, 2020
Talking investment with Octopus Ventures’ Uzma Choudry and what she’s looking for in a breakthrough technology.
Next week, the first Biohacking Congress will be held in London, bringing together famous biohackers, renowned scientists, healthcare professionals, researchers, authors and investors focused on helping us all live a longer and healthier life.
A key component of the event is a start-up competition, which is part of the Startup World Cup, a global competition with a grand prize of $1 million. Seed and Series A level start-ups from MedTech, digital health, biotech and healthcare will pitch to a panel of experts at Biohacking Congress, including Uzma Choudry, PhD, an investor at Octopus Ventures.
With more than £1 billion under management today, Octopus Ventures started out as a generalist Venture Capital (VC) firm, but in recent years has focused on three key pillars of investment: Deep Tech, Future of Money and Future of Health.
Uzma is focused on assessing investment opportunities, conducting preliminary due diligence and executing deals. Her experience straddles the Deep Tech and Future of Health Pods, and she is now focused on Frontier Technologies within health and biotech such as synthetic biology and nanotech, genomics, gene editing and computational biology. This includes platforms at the intersection of technology and biology, including human augmentation and neurotech.
“We’re starting to build more expertise in the frontier technologies within health and seeing a number of life sciences opportunities which fit in that bracket,” she says. “And that’s where we feel there’s an overlap between deep tech and health.”
“… we asked ourselves whether Longevity is a space we should be looking at? … We think it is because the areas that we want to look at are those where we think there is a large opportunity or big global challenges that we could be solving. Longevity certainly ticks that box …”
In terms of biohacking specifically, Choudry, with a PhD in synthetic biology and biophysics, has a keen personal interest. She points at the opportunity presented by advancements in the genomics space – initially around the ability to read the “biological” software (genome) through more cost-effective DNA sequencing technology, but further now in developments around gene editing tools, such as CRISPR-Cas3/9, which provide the ability to write and edit the software/genes, and opening up a massive opportunity.
0 0 0
Definitely "high quality" ...Gla :-)
Trusted financial solutions
UK’s largest provider of VCTs, EIS and BPR-qualifying investments
£9.1 billion under management*
120+ investment professionals
*At 30 September 2020
We’re part of Octopus Group
Established in 2000, Octopus is a group of businesses investing in people, ideas and industries that change the world. You might know us through our energy company, Octopus Energy. Learn more at octopusgroup.com.
Wonder if we're now in this
Nice to see an II with a decent investment in the placing - Octopus Investments 8%